Insider Selling Wave Sweeps High-Multiple Growth and Biotech Names
Snowflake, Rhythm Pharmaceuticals and Krystal Biotech executives lead more than $40 million in disclosed disposals, with Dutch Bros the rare insider buy
A dense cluster of Form 4 filings shows heavy insider distribution across software and biotechnology, led by a $16.8 million Snowflake director sale and roughly $15.5 million of combined Rhythm Pharmaceuticals executive sales, while insider buying was limited to a single Dutch Bros board purchase.